References
- Stone P. H., Antman E. M., Muller J. E., Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann. Int. Med. 1980; 93: 886–904
- Martindale. The Extra Pharmacopoeia. Twentyeighth Edition, J. E. F. Reynolds, A. B. Prasad. The Pharmaceutical Press, London 1982; 1628–1629
- Heidland A., Heidbreder E., Hörl W. H., Schäfer R. Calcium antagonists in the treatment of hypertension. Contrib Nephrol. 1982; 33: 254–269
- Terry R. W. Nifedipine therapy in angina pectoris: Evaluation of safety and side effects. Am Heart J. 1982; 104: 681–689
- Lewis J. G. Adverse reactions to calcium antagonists. Drugs. 1983; 25: 196–222
- Dyrszka H., Wahn B. Klinisches Bild und Therapie einer uberdosis des Koronartherapeutikums Nifedipine (Adalat). Inn Med. 1977; 4: 31–34
- Books N., Cattell M., Pidgeon J., Balcon R. Unpredictable response to nifedipine in severe cardiac failure. Br. Med J. 1980; 281: 1324
- Madera F., Wenger R. Zur Frage von Vergiftung mit Isoptin S (Verapamil + Pentobarbital). Intensivmed. 1977; 14: 373–377
- Perkins C. M. Serious verapamil poisoning: treatment with intravenous calcium gluconate. Br Med J. 1978; II: 1127
- Da O. A., Silva R. A., De Melo J. P., Filho J. Verapamil acute self-poisoning. Clin Toxicol. 1979; 14: 361–367
- Moroni F. P.F. Mannaioni, Dolera A., Ciaccheri M. Calcium gluconate and hypertonic chloride in a case of massive verapamil poisoning. Clin Toxicol. 1980; 17: 395–400
- Morris D. L. Calcium infusion for reversal of adverse effects of intravenous verapamil. JAMA 1983; 249: 3212–3213
- Heidland A., Klütsch K., Öbek A. Myogenbedingte Vasodilatation bei Nierenischämie.Münch Med Mschr. 1962; 35: 1636–1637
- Bertel O., Conen D. E., Radü W., Müller J., Lang C. U., Dubach C. Nifedipine in hypertension emergencies. Br Med J. 1983; 286: 19–21
- Raemsch K. D., Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension. 1983; 5: 18–24, supp II
- Banzet O. J., Colin N., Thibonnier M., Singlas E. J., Alexandre M., Corvol P. Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine. Eur J Clin Pharmacol. 1983; 24: 145–150
- Rosenkranz H., Schlossmann K., Scholtan W. Die Bindung von 4- (2- Nitrophenyl) -2, 6-dimenthy1 -1,4-dihydro-pyridin-3,5-dicarbonsäure-dimenthylester (Nifedipine) sowie von anderen koronarwirksamen Stoffen an die Eiweißkörper des Serums. Arnzeim Forsch. 1974; 24: 455–466
- Eliahou H. E., Iaina A., Schneider R., Cohen D., Goldfarb D., Gross M. Treatment of hypertension in dialysis and essential hypertension patients with nifedipine. Clin. Exp. Dialysis and Apheresis. 1982; 6: 229–236
- Kusano E., Asano Y., Takeda K., Matsumoto Y., Ebihara A., Hosoda S. Hypotensive effect of nifedipine in hypertensive patients with chronic renal failure. Arzneim Forsch. 1982; 32: 1575–1580
- Hamann S. R., Mc Allister R. G., Jr. Plasma concentrations and hemodynamic effects of nifedipine: A study in anesthetized dogs. J Cardiovasc Pharmacol. 1983; 5: 920–927
- Bianchetti M. G., Beretta-Piccoli C., Weidmann P., Link L., Boehringer K., Ferrier C., Morton J. J. Calcium and blood pressure regulation in normal and hypertensive subjects. Hypertension. 1983; 5: 57–65, supp II